Agilent Q3 earnings beat estimates on revenue and EPS, with China and pharma growth prompting an upgraded full-year forecast.

The FDA's pancreatic cancer drug approval for Revolution Medicines' daraxonrasib lands months early, but the stock barely ...

Abbott's Libre Duo 10 Day wins FDA authorisation as the first dual glucose-ketone sensor, opening a new front in ...

Boston Scientific cyberattack disrupts global order processing and shipping; shares fall as investigation into the breach ...

McKesson's Precision Medicine Group acquisition, worth ~$2.25bn, deepens its push into oncology and specialty services, ...

CrowdStrike raises full-year guidance after Q2 net new ARR hit $333m, up 51% year-on-year, sending shares up 10.63% on 5 June ...

Majedie Investments (MAJE) posted a Majedie Investments NAV return of +10.7% for the quarter to 30 June 2026, beating the trust’s CPI-plus-4% annualised objective and lifting the year-to-date NAV ...

Lloyds Banking Group half-year profit rose to £4.3bn in the six months to 30 June, up from £3.5bn a year earlier, as the bank ...

Dick's Sporting Goods stock plunge wiped a quarter of its value after a $31.9m Foot Locker loss and a cut to full-year profit ...

OpenAI's data centers chief Chris Malone has left the company, the latest in a run of senior exits ahead of a planned 2027 ...

The Greggs interim results 2026 sent the baker’s shares up 16.1% on 29 July, extending a two-day gain to roughly 23.4% since ...

Canada retaliatory tariffs of up to 50% hit $20bn of US goods from 8 September, matching Washington's levies ...